| INTRODUCTION
Ubiquinone 1 and ubiquinol 2, referred [1] [2] [3] [4] [5] [6] to as coenzyme Q 10 , exhibit a chemically intriguing framework of long polyprenylated side chains (10 units) functionalized onto benzoquinone or benzoquinol units. According to their redox states, ubiquinone and ubiquinol are classified into oxidized and reduced forms, respectively. Indeed, these compounds, which are described as vitamin-like substances, play crucial roles in controlling the antioxidant activity to protect cells from free radicals and act as essential electron carriers in mitochondria, which converts the energy in carbohydrates and fatty acids into ATP. [1] [2] [3] [4] [5] [6] A healthy human body maintains regular biosynthetic functions to produce enough amounts of ubiquinone and ubiquinol, but their production tends to decrease with chronological age. [4] [5] [6] Therefore, dietary or supplemental intake of ubiquinone and ubiquinol is recommended with advancing age. However, there is little information on their in vivo pharmacokinetics, and the difference between ubiquinone and ubiquinol in living systems is not well known. Therefore, in this investigation, we focused on using positron emission tomography (PET), which is capable of recording dynamic images of accumulation and distribution of ubiquinone and ubiquinol in tissues or the whole body. Here, we report the synthesis of 11 C-labeled ubiquinone [ 
| RESULTS AND DISCUSSION
The radiochemistry group of Tohoku University already reported the synthesis of 11 ]methylation, which was initially planned via a two-step metathesis consisting of ethylenation and borylpropenation (Scheme 2, path A). A study of previously reported metathesis methods for introducing vinylborane 23 indicated that the less hindered terminal ethylene of 39,39-didemethyl ubiquinone 4 is a requisite moiety, owing to the reactivity required for olefin metathesis with 2-(pinacolboryl)propene. However, we encountered difficulties in synthesizing the terminal ethylene compound 4 by Ru-catalyzed ethenolysis of 1 as the first step. As shown in Figure 1 , the metathesis reaction of 1 (430 mg, 500 μmol) with ethylene (3 bar) in an autoclave apparatus in toluene (10 mL) at 100°C for 3 hours using a second-generation Hoveyda-Grubbs catalyst 24 (0.8 mg, 1.3 μmol, approximately 0.3 mol%) resulted in nonselective ethenolysis compounds, 25 including not only the desired compound 4 but also polyprenyl side-chain-shortened by-products 5, 6, and 7. The yield of 4 was up to 17%. The reaction conditions were further investigated by modulating the solvent (acetic acid, heptane, and methyl tert-butyl ether), temperature (50°C-120°C), time (0.5-21 h), ethylene gas pressure (1-3 bar), and catalyst content (0.1-1.0 mol%), but we could not overcome the shortcomings related to low selectivity and reactivity. As it was difficult to obtain SCHEME 1 Synthesis of [ 11 C] ubiquinone and [ 11 C] ubiquinol from ubiquinone terminal ethylene 4 at a high yield, we adopted path B, which is a one-step metathesis of 1 and 2-(pinacolboryl) propene.
For the metathesis reaction in path B, three popular catalysts, the first-generation Piers catalyst, 26 second-generation Hoveyda-Grubbs catalyst, 24 and the Stewart-Grubbs catalyst, 27 were used.
Interestingly, usage of the second-generation HoveydaGrubbs catalyst resulted in a high reactivity and reaction at 70°C in toluene yielded the desired pinacolboryl compound 3 (up to 16% yield, Table 1 , entry 3). However, as shown in the liquid chromatography/time-of-flight mass spectrometry (LC/TOF-MS) analysis of the products (Figure 2 ), the molecular weights of each of the peaks indicated that a considerable amount of polyprenyl sidechain-shortened by-products 8 to 15 (prenyl unit number: n = 1-8) was produced and the total yield of the byproducts was 54%. The reaction conditions were further investigated in terms of the catalyst concentration and reaction time (Table 1 , entries 1, 2, 4, and 5), but the yields of 3 were not very different from the result shown in entry 3. Meanwhile, reactions using the firstgeneration Piers catalyst or the Stewart-Grubbs catalyst resulted in 3 at trace amounts (less than 5%). Even though path B using the second-generation HoveydaGrubbs catalyst resulted in a low yield of 16%, we concluded that this one-step procedure was useful for preparing 3 at a yield of several hundred milligrams.
To purify 3, a metal-ion scavenger was used to remove Ru metal from the reaction mixture. Later, the residue was purified by silica-gel column chromatography to afford crude 3 with 28% purity. Subsequently, sizeexclusion chromatography was conducted to obtain 3 with 89% purity. In order to further increase the purity level, one more iteration of silica-gel column chromatography was carried out to obtain greater than 97% pure 3 ( Figure 3 ). High-performance liquid chromatography (HPLC) analysis showed that the purified 3 was an 11:1 trans-cis mixture with respect to terminal 2-(pinacolboryl)propene ( Figure 3 ).
Using precursor 3, the synthesis of . According to the procedure described in a previous report, 7 we set up the 11 C-labeling conditions of [ 11 C]CH 3 I (radioactivity: 20-40 GBq), which included 3 (2.6 mg, 2.7 μmol), Pd 2 (dba) 3 (1.4 mg, 1.5 μmol), and P(o-tolyl) 3 (1.9 mg, 6.2 μmol) in dimethylformamide (DMF, 450 μL). The reaction was carried out at 65°C for 4 minutes. As shown in Figure 4A , which illustrates a semipreparative HPLC chromatogram of the reaction mixture, the desired compound [ 11 C]-1 was clearly indicated by a major peak. After radiopharmaceutical formulation using a solution of saline, propylene glycol, and Tween 80 (volume ratio: 100/10/0.5), the radioactivity and molar activity of [ 11 C]-1 at the end of the synthesis were confirmed to be 1.5 GBq in normal cases (obtained radioactivity range: 0.4-3.5 GBq) and 21 to 78 GBq/μmol, respectively. The total synthesis time was less than 36 minutes, and the radiochemical yield based on [ 11 C]CH 3 I was up to 53%. The radiochemical purity and chemical purity were found to be greater than 99% ( Figure 4B and 4C). The pH value was approximately 7. These qualities fully met the criteria for animal PET studies.
To In fact, during the HPLC analysis of [ The reaction of 1 (1.0 g, 1.2 mmol) with 2-(pinacolboryl)propene (0.8 g, 4.8 mmol) in toluene (12 mL) was carried out at a specified reaction temperature and concentration (mol%) of the Hoveyda-Grubbs catalyst, as shown in each entry of Table 1 .
In order to protect [ 11 C]-2 from both radiolysis and oxidation, we employed ascorbic acid as a radical scavenger and an antioxidant. 28 Ascorbic acid was added to all the used solutions, such as the HPLC eluent, any remaining solution inside the rotary evaporator, and injection solution, which were necessary for the purification of [ C]-2 at the end of the synthesis were found to be 1.2 GBq in normal cases (obtained radioactivity range: 0.16-1.4 GBq) and 48 to 76 GBq/μmol, respectively. The radiochemical purity and chemical purities of the obtained product were greater than 95% and around 77%, respectively, which were calculated by the ratios of the corresponding peak areas in analytical HPLC chromatogram. (Figure 5C and 5D). Synthesis was accomplished within 38 minutes, and the radiochemical yield based on [ These biological studies will be reported separately in a forthcoming paper.
| CONCLUSIONS
We successfully synthesized 11 UV-HPLC; the large peak around 0.5 to 4.5 min is mainly attributed to the use of ascorbic acid that is used as an additive are currently in progress. After synthesizing highly pure [ 11 C]-2 (greater than 98%), we will move on to clinical PET studies as our ultimate goal.
| EXPERIMENTAL SECTION

| General methods
All reagents and solvents were used as received from their commercial sources without further purification. LC/TOF-MS (Bruker Daltonik UHR-TOF maXis 4G) was conducted to estimate the prenyl unit chain length of the products by the metathesis reaction of ubiquinone. Gel-permeation chromatography was used to purify the desired pinacolboryl precursor 3 from crude products with different chain lengths of the prenyl unit. Pd-mediated C-[ 11 C] methylation was conducted in a lead-shielded hot cell operated by remote control. [ 11 C] Carbon dioxide was produced by a 14 N(p,α) 11 C nuclear reaction using a 12-MeV cyclotron and then converted to [ 11 C]CH 3 I by treatment with lithium aluminum hydride followed by hydriodic acid using an automated radiolabeling system, which involved heating the reaction mixture, dilution, HPLC injection, fractional collection, evaporation, and sterile filtration. The radioactivity of the compound was quantified with a dose calibrator. Semipreparative purification and purity analysis by HPLC were performed on a system equipped with pumps and an ultraviolet (UV) absorption detector, while the radioactivity of the effluent was determined using a radio analyzer. The radiochemical yield of the desired 11 C-labeled product was shown as the conversion yield based on the initial radioactivity [ Table 1) To a mixture of ubiquinone 1 (1.0 g, 1.2 mmol), a second-generation Hoveyda-Grubbs catalyst (22.5 mg, 36 μmol) in toluene (12 mL) and 2-(pinacolboryl) propene (0.8 g, 4.8 mmol) were added. The reaction flask was evacuated and filled with N 2 gas four times, after which the mixture was heated at 70°C for 2 hours. After cooling the reaction mixture to room temperature, a metal-ion scavenger (QuadraSil AP) was added and the mixture was stirred for 1 hour. The suspended solution was filtered and washed with ethyl acetate. After removing the solvent under reduced pressure, a part of the residue was analyzed by LC/TOF-MS (Figure 2) . Most of the residue was purified by flash-column chromatography on silica gel (hexane and a 30:1 solution of hexane and ethyl acetate) to yield a crude product. The crude product was further purified by gelpermeation chromatography using tetrahydrofuran (THF) as the eluent and flash-column chromatography on silica gel to afford the desired compound, 39-demethyl-39-(pinacolboryl)ubiquinone 3, as a colorless oil (up to 16 % yield, normal cases after the severe purification: 54 mg, 5% yield). Analytical HPLC; YMC-Pack Pro C18 150 × 4.6 mm I.D., eluent: methanol/hexane = 9:1, flow rate: 1.0 mL/min, UV: 290 nm, column temperature: 30°C, retention times of 3: 18.2 and 19.5 minutes for trans and cis isomers, respectively, at a ratio of 11:1 ( Figure 3 To analyze the reactivity and suitability of the 11 C-labeling system, a solution of the pinacolboryl precursor 3 (5.8 mg, 6.0 μmol), Pd 2 (dba) 3 (2.9 mg, 3.17 μmol), and P(o-tolyl) 3 (3.8 mg, 12.5 μmol) in DMF (450 μL) was used. The resulting mixture was heated at 65°C by hot air for 4 minutes and then diluted with DMF (0.7 mL). The mixture was transferred to a reservoir vessel using a rinse solution of DMF (0.2 mL). After passing through a cotton filter, the mixture was injected into a semipreparative HPLC system (mobile phase Figure 4A ). The fraction of interest was collected in a flask containing H 2 O (2.0 mL) and concentrated under reduced pressure. In accordance with the radiopharmaceutical formulation, the desired product [ 11 C]-1 was dissolved in a mixed solution (1.6 or 2.2 mL) of saline, propylene glycol, and Tween 80 (volume ratio: 100/10/0.5) to be collected in a sterilized vial. The collection operation was repeated twice. The total synthesis time including 11 C-labeling reaction, HPLC purification, and radiopharmaceutical formulation was less than 36 minutes. The radioactivity of the formulated injection solution of [ 13.5-14.5 minutes; see Figure 5A ). The fraction of interest was collected in a flask containing H 2 O (2.0 mL) and ascorbic acid (5.0 mg, 28.3 μmol) followed by concentration under reduced pressure to remove the solvent. In accordance with the radiopharmaceutical formulation, HPLC analysis conditions for Figure 5B ; mobile phase: ethanol/methanol = 15/85; column: COSMOSIL 5C18 PAQ 4.6 × 150 mm; flow rate: 1.0 mL/min.
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